Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31366603 | 1.00 | RECQL (0.51) | RECQLCNR1CNR2FADS1ALDH1A1 | |
| SCHEMBL1342696 | 0.98 | RECQL (0.53) | RECQLCNR1CNR2FADS1ALDH1A1 | |
| SCHEMBL25298952 | 0.95 | RECQL (0.53) | RECQLFADS1ALDH1A1KDM4EMGLL | |
| SCHEMBL30590434 | 0.92 | RECQL (0.56) | RECQLFADS1ALDH1A1KDM4EMGLL | |
| SCHEMBL2471282 | 0.92 | RECQL (0.56) | RECQLFADS1ALDH1A1KDM4EMGLL | |
| Hydrochloric Acid SCHEMBL9115524 | 0.90 | RECQL (0.54) | RECQLFADS1ALDH1A1KDM4EMGLL | |
| SCHEMBL5278117 | 0.87 | ALDH1A1 (0.52) | RECQLCNR1CNR2ALDH1A1KDM4E | |
| SCHEMBL13391055 | 0.86 | RECQL (0.50) | RECQLFADS1ALDH1A1MGLLKMT2A | |
| SCHEMBL5326364 | 0.85 | ALDH1A1 (0.50) | RECQLCNR1CNR2ALDH1A1KDM4E | |
| SCHEMBL14141253 | 0.83 | ALDH1A1 (0.52) | RECQLCNR1CNR2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197360-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE | 2025-06-19 | — | — | US | disclosed |
| EP-4276188-A1 | METHOD FOR SYNTHESIZING CHIRAL AMINE COMPOUND | Asymchem Laboratories (Tianjin) Co., Ltd. (CN) | 2023-11-15 | — | — | EP | disclosed |
| EP-4273237-A1 | TRANSAMINASE MUTANT AND APPLICATION THEREOF | Asymchem Laboratories (Tianjin) Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023172726-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172726-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE (US) | 2023-09-14 | — | — | WO | disclosed |
| US-11021448-B2 | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases | HOFFMANN-LA ROCHE INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3535253-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-20190256478-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-7906538-B2 | Parasiticides; nematocides; crop protection | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2011-03-15 | — | — | US | disclosed |
| US-20080262048-A1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2008-10-23 | — | — | US | disclosed |
| US-7312248-B2 | Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| CN-101065352-A | Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives | SCHERING PLOUGH LTD (CH) | 2007-10-31 | — | — | CN | disclosed |
| EP-1799636-A2 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES | Schering-Plough Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006034333-A2 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES | SCHERING-PLOUGH LTD. (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063841-A1 | Parasiticides; nematocides; crop protection | SCHERING-PLOUGH LTD. (CH) | 2006-03-23 | — | — | US | disclosed |
| US-5578633-A | VASOPRESSIN AND OXYTOCIN ANTAGONISTS | SANOFI (FR) | 1996-11-26 | — | — | US | disclosed |
| US-5481005-A | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1996-01-02 | — | — | US | disclosed |
| US-5397801-A | Affinity for vasopressin and ocytocin receptors; disorders of nervous, cardiovascular and gastrointestinal systems | SANOFI (FR) | 1995-03-14 | — | — | US | disclosed |
| US-5338755-A | Have affinity for vasopressin and ocytocin receptors; intermediates for drugs that act on central nervous system | ELF SANOFI (FR) | 1994-08-16 | — | — | US | disclosed |
| US-3950526-A | Quinazoline derivatives in pharmaceutical compositions for treating pain and inflammation | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063841-A1 | Parasiticides; nematocides; crop protection | TRHDE, DDT, EPHX1 | RECQL 4453/4885CNR1 485/4885CNR2 500/4885 |
| US-11021448-B2 | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases | CHRM1, CHRM2, CHRM4 | RECQL 3666/4885CNR1 6/4885CNR2 28/4885 |
| US-20080262048-A1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES | TRHDE, EPX, EPHX1 | RECQL 4235/4885CNR1 925/4885CNR2 822/4885 |
| US-20190256478-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | CHRM1, CHRM2, CHRM4 | RECQL 3666/4885CNR1 6/4885CNR2 28/4885 |
| US-20250197360-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | CUL4B, BRD4, CUL4A | RECQL 390/4885CNR1 1610/4885CNR2 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.